Abbott faces second FTC probe over baby formula shortage

Bloomberg

Abbott Laboratories is facing another probe into its role in last year’s baby formula shortage that left millions of American families scrambling for vital nutrition products.
Last month, Abbott received a civil investigative demand from the US Federal Trade Commission seeking information in connection with its probe of companies that participate in bids for formula contracts, according to a financial statement filed with the US Securities and Exchange Commission.
The investigation could lead to a lawsuit by the FTC if the agency finds Abbott engaged in anticompetitive conduct, such as collusion with other manufacturers on pricing.
For decades, Abbott and peers Perrigo Co, Nestle SA and Mead Johnson Nutrition Company have held tight control over the infant formula market in the US.
The risks from that level of market consolidation were brought into sharp relief last year, when millions of formula cans were recalled from Abbott’s plant in Sturgis, Michigan after several infants got sick.
The plant was shutdown, which led to a nationwide shortage of powdered infant formula. Abbott’s plant in Sturgis had been making about 20% of the country’s infant formula, including Similac, the country’s most popular brand. Some 70 million cans and containers of Similac, as well as the specialty formulas EleCare and Alimentum, were recalled a year ago.
Other companies ramped up production and the US government loosened import restrictions to counteract the shortage, but shelves remained bare and families struggled to get their hands on essential formula for their infants.
Abbott’s disclosure shows the US government is still looking into the issue months after authorities vowed to hold companies responsible for their roles in the shortages. The US Justice Department has also launched a criminal investigation related to Abbott’s manufacturing of formula, the company confirmed last month. Abbott in May entered a five-year consent decree with the DOJ that gives the US Food and Drug Administration (FDA) additional oversight of the Sturgis facility.
The company also received a subpoena from the SEC’s Enforcement Division requesting information relating to Abbott’s powder infant formula business and related public disclosures, according to the filing.